{"gene":"FSTL3","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":1998,"finding":"FSTL3 (FLRG) encodes a secreted glycoprotein belonging to the follistatin-module-protein family, identified from a chromosomal translocation t(11;19)(q13;p13) in B-cell chronic lymphocytic leukemia, establishing it as a novel secreted protein of the follistatin family.","method":"cDNA cloning and molecular characterization of chromosomal translocation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — molecular cloning with sequence analysis and expression studies, single lab but foundational characterization","pmids":["9671416"],"is_preprint":false},{"year":2001,"finding":"FSTL3 (FLRG) binds activin A, as demonstrated by immunoprecipitation and Far-Western blot analysis, and its expression in bone marrow stromal cells is dramatically upregulated by TGF-β at both mRNA and protein levels.","method":"Immunoprecipitation, Far-Western blot, RT-PCR, Northern blot","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal binding assays (IP and Far-Western), single lab, two orthogonal methods","pmids":["11274757"],"is_preprint":false},{"year":2001,"finding":"FSTL3 (FSRP) binds activin with similar affinity and selectivity as follistatin but does not bind heparin. FSTL3 inhibits activin-mediated gene transcription in heterologous assays but is much less active than follistatin in the rat pituitary bioassay. Overexpression in transgenic mice disrupts follicular development and fertility in females.","method":"Binding assays, transcriptional reporter assay, pituitary bioassay, transgenic mouse overexpression","journal":"Molecular and cellular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods (binding, reporter, bioassay, transgenic), single lab","pmids":["11451569"],"is_preprint":false},{"year":2001,"finding":"TGF-β induces FSTL3 (FLRG) transcription through Smad proteins binding to a Smad-binding element in the FLRG promoter. Dominant-negative Smad3 and Smad4 mutants block TGF-β-induced transactivation. Smad3 and Smad4 proteins directly bind the SBE motif in the FLRG promoter as shown by EMSA.","method":"Promoter reporter assay, deletion/point-mutation analysis, dominant-negative Smad transfection, EMSA (gel shift)","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Strong — promoter mutagenesis, dominant-negative functional validation, and direct DNA-binding EMSA in one study; mechanistic detail replicated in follow-up papers","pmids":["11571638"],"is_preprint":false},{"year":2002,"finding":"FSTL3 (FLRG) protein inhibits activin A signaling in transcriptional reporter assays and blocks activin A-induced growth inhibition of HepG2 cells. Activin A induces FSTL3 and follistatin expression via Smad proteins, and FSTL3 protein in turn regulates its own activin-induced expression, constituting a negative feedback loop.","method":"Transcriptional reporter assay, cell growth assay, phospho-Smad2 analysis, Smad transfection","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (reporter, growth inhibition, feedback regulation), replicated Smad mechanism from prior work, two independent labs","pmids":["11948405"],"is_preprint":false},{"year":2003,"finding":"FSTL3 binds activin B approximately 10-fold less potently than activin A, and is approximately 3-fold more effective in neutralizing activin A relative to activin B in reporter assays, demonstrating differential binding and neutralization specificity.","method":"Binding assays, 293 cell reporter assays for neutralization","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative binding and functional neutralization assays, single lab, two orthogonal methods","pmids":["12697670"],"is_preprint":false},{"year":2004,"finding":"FSTL3 lacks a heparin-binding sequence and cannot associate with cell surfaces or heparin, unlike follistatin. Insertion of the full follistatin domain 1 (containing the HBS) into FSTL3 conferred heparin binding but abolished activin binding, implying an evolutionary safeguard against surface binding by FSTL3.","method":"Mutational analysis, cell surface binding assay, heparin affinity binding, competitive activin binding, pituitary cell FSH secretion bioassay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 1 / Strong — systematic mutagenesis with multiple functional readouts (heparin binding, cell surface binding, activin binding, bioassay), single lab but multiple orthogonal methods","pmids":["15471966"],"is_preprint":false},{"year":2005,"finding":"FSTL3 (FLRG) physically interacts with human fibronectin; the interaction is mediated by type I motifs of fibronectin and follistatin domains of FSTL3/follistatin. This interaction increases adhesion of hematopoietic cells to fibronectin in a dose-dependent manner, including immature hematopoietic precursors (CFC, LTC-IC).","method":"Yeast two-hybrid screen, co-immunoprecipitation/pulldown, cell adhesion assay with primary hematopoietic cells and cell lines","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus functional adhesion assay, single lab, two orthogonal methods","pmids":["16336961"],"is_preprint":false},{"year":2005,"finding":"FSTL3 (FLRG) directly interacts with ADAM12 via its cysteine-rich domain, as identified by yeast two-hybrid and confirmed by direct interaction assay. FSTL3 protein inhibits osteoclast differentiation from murine primary spleen cells and RAW264.7 macrophages stimulated with RANK-L and M-CSF, reducing osteoclast number and nuclei per osteoclast.","method":"Yeast two-hybrid screen, direct protein interaction assay, osteoclast differentiation assay (primary spleen cells and RAW264.7 cells)","journal":"Biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid plus functional cellular assay with primary cells, single lab, two orthogonal methods","pmids":["15574124"],"is_preprint":false},{"year":2007,"finding":"TNF-α activates FSTL3 (FLRG) transcription through NF-κB binding to four tandem 107-108 bp DNA repeats in the FLRG promoter, each containing an NF-κB responsive element (5'-GGGAGAG/TTCC-3'). TGF-β through Smad proteins potentiates TNF-α-induced FSTL3 expression.","method":"Promoter reporter assay, deletion analysis, phylogenetic footprinting, NF-κB binding assay","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter deletion analysis with functional reporter assay and binding studies, single lab","pmids":["17395406"],"is_preprint":false},{"year":2007,"finding":"FSTL3 knockout adult mice develop increased pancreatic islet number and size, beta cell hyperplasia, decreased visceral fat mass, improved glucose tolerance, and enhanced insulin sensitivity, attributable to increased activin and myostatin bioactivity in specific tissues in the absence of the FSTL3 antagonist.","method":"Homozygous FSTL3 knockout mouse model with metabolic phenotyping (glucose tolerance, insulin sensitivity, histomorphometry)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean KO with multiple defined metabolic phenotypes and mechanistic attribution to activin/myostatin signaling, multiple phenotypic readouts","pmids":["17229845"],"is_preprint":false},{"year":2007,"finding":"FSTL3 (FLRG) silencing in breast cancer cell lines restores endogenous activin signaling (increased phospho-Smad2 and activin target gene transcripts), causes growth inhibition reversible by exogenous FSTL3 or soluble type II activin receptor, demonstrating FSTL3 promotes tumor cell proliferation by antagonizing endogenous activin.","method":"siRNA silencing, phospho-Smad2 western blot, gene expression analysis, cell growth assay, receptor rescue experiment","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 / Strong — loss-of-function with multiple mechanistic readouts (signaling, rescue), defined pathway placement via activin receptor rescue","pmids":["17671190"],"is_preprint":false},{"year":2007,"finding":"Nuclear FSTL3 (FLRG) interacts with AF10 (MLL fusion partner) via AF10's N-terminal PHD domain. FSTL3 enhances AF10 homo-oligomerization and increases AF10-mediated transcriptional activation in transient transfection assays, revealing an intranuclear transcriptional co-regulatory function.","method":"Yeast two-hybrid, Far-Western blot, co-immunoprecipitation in COS-7 cells, oligomerization assay, Gal4-fusion transactivation assay","journal":"Biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple binding assays (Y2H, Far-Western, Co-IP) plus functional transcription assay, single lab","pmids":["17868029"],"is_preprint":false},{"year":2008,"finding":"X-ray crystal structure of FSTL3 in complex with activin A (2.5 Å resolution) shows two FSTL3 molecules encircling the ligand and blocking all receptor-binding sites. The FSTL3 N-terminal domain makes more intimate contact with activin A than the corresponding follistatin domain, and replacing the FSTL3 N-terminal domain with the follistatin N-terminal domain considerably lowers activin A affinity, explaining FSTL3's specificity.","method":"X-ray crystallography, domain-swap binding studies","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — high-resolution crystal structure combined with biochemical mutagenesis/domain-swap validation, mechanistic detail at atomic resolution","pmids":["18768470"],"is_preprint":false},{"year":2013,"finding":"FSTL3 knockout mice develop markedly enlarged testes with increased Sertoli cell numbers and enhanced spermatogenesis, and show delayed age-related testicular regression. FSTL3 deletion leads to increased AKT signaling and SIRT1 expression in the testis, demonstrating cross-talk between TGF-β ligand and AKT signaling pathways.","method":"FSTL3 knockout mouse model, histomorphometry, western blot for AKT/SIRT1 signaling","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO model with defined cellular phenotype and signaling pathway analysis, single lab","pmids":["23407452"],"is_preprint":false},{"year":2016,"finding":"In FSTL3 knockout mice, α-to-β cell transdifferentiation is increased, as demonstrated by Gluc-Cre/YFP lineage tracing showing significantly more Ins+/YFP+ cells versus wild-type. Activin treatment of isolated islets significantly increased YFP+/Ins+ cells, demonstrating that activin signaling (released from FSTL3 antagonism) drives this transdifferentiation.","method":"Gluc-Cre/YFP α-cell lineage tracing, flow cytometry, fluorescent cell counting in pancreatic sections, activin treatment of isolated islets","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic lineage tracing with flow cytometry and histological confirmation, plus pharmacological activin treatment, multiple orthogonal methods","pmids":["26727106"],"is_preprint":false},{"year":2019,"finding":"FSTL3 promotes lipid accumulation in macrophages and upregulates scavenger receptors CD36 and LOX-1 in a dose-dependent manner. FSTL3 also induces secretion of inflammatory cytokines (IL-1β, MCP-1, TNF-α, MMP-9) in macrophages. Oxidized LDL induces FSTL3 expression and secretion.","method":"Cell treatment assays, western blot for CD36/LOX-1, ELISA for cytokines, lipid accumulation assay, FSTL3 knockdown","journal":"Journal of cardiovascular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dose-dependent functional assays with knockdown controls, single lab","pmids":["31815869"],"is_preprint":false},{"year":2021,"finding":"FSTL3 binds to transcription factor c-Myc (at amino acids 354–406), suppresses c-Myc ubiquitination and increases its stability, thereby upregulating PDL1 and IDO1 expression to promote tumor immune evasion in colorectal cancer. FSTL3 expression in CRC cells is induced by hypoxia via HIF1α.","method":"Co-immunoprecipitation, ubiquitination assay, western blot, FSTL3 knockout immunocompetent tumor models, flow cytometry for immune cell populations","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP with specific domain mapping (aa354-406), ubiquitination assay, in vivo KO model with immune phenotyping, single lab","pmids":["38302412"],"is_preprint":false},{"year":2021,"finding":"An FSTL3-neutralizing antibody (FP-101) that selectively disrupts FSTL3-activin complexes (without affecting follistatin) enhances glucose-responsive insulin secretion from dysfunctional mouse and human islets in vitro under conditions modeling diabetes.","method":"Neutralizing antibody development, in vitro activin-complex disruption assay, insulin secretion assay from mouse and human islets","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological neutralization with selectivity characterization and functional islet readout, single lab","pmids":["33539535"],"is_preprint":false},{"year":2024,"finding":"Prenatal dexamethasone exposure increases KDM1B expression in fetal testicular Sertoli cells, which decreases H3K9me2 levels at the FSTL3 promoter, thereby epigenetically upregulating FSTL3 expression. Increased FSTL3 inhibits TGF-β signaling and reduces CX43/E-cadherin expression, impairing blood-testis barrier function and sperm quality.","method":"ChIP for H3K9me2 at FSTL3 promoter, western blot, dexamethasone treatment of TM4 Sertoli cells, in vivo rat model","journal":"Acta pharmacologica Sinica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating epigenetic regulation of FSTL3 promoter with functional consequence in Sertoli cells, validated in vivo and in vitro, single lab","pmids":["38472317"],"is_preprint":false},{"year":2025,"finding":"FSTL3 expressed by cancer-associated fibroblasts binds to transferrin receptor (TfR1) on cancer cells, activating the TfR1/AKT/mTOR pathway and elevating VE-Cadherin to support endothelial-like transformation, vasculogenic mimicry, and metastatic progression in colon cancer. FSTL3-targeting antibodies inhibited vasculogenic mimicry and synergized with bevacizumab.","method":"Co-immunoprecipitation/binding assay, single-cell RNA sequencing, in vitro and in vivo functional assays, antibody neutralization","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding interaction with functional pathway activation demonstrated in vitro and in vivo, single lab","pmids":["41053124"],"is_preprint":false},{"year":2025,"finding":"FSTL3 loss in OSCC cells induces cuproptosis susceptibility by suppressing SLC25A10, leading to mitochondrial succinate accumulation, succinate-driven succinylation and upregulation of DLAT (essential for cuproptosis execution), thereby suppressing lymph node metastasis.","method":"CRISPR-Cas9 screening, knockdown studies, metabolomics for succinate, succinylation assay, in vivo metastasis models","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen followed by mechanistic validation of SLC25A10/succinate/DLAT axis, single lab, multiple methods","pmids":["41996175"],"is_preprint":false},{"year":2025,"finding":"ZNF454 binds directly to the FSTL3 promoter (confirmed by ChIP and dual-luciferase assay) and transcriptionally represses FSTL3, which in turn suppresses HIF-1α-mediated glycolysis in colorectal cancer cells under hypoxic conditions. FSTL3 overexpression reverses ZNF454-mediated suppression of proliferation, migration, invasion, and glycolysis.","method":"ChIP assay, dual-luciferase reporter assay, RT-qPCR, western blot, metabolic flux assays (ECAR/OCR), in vivo xenograft","journal":"Journal of gastrointestinal oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and luciferase with functional rescue experiments, single lab","pmids":["41522747"],"is_preprint":false}],"current_model":"FSTL3 is a secreted glycoprotein that acts as an extracellular antagonist of TGF-β superfamily ligands (primarily activin A, activin B, and myostatin) by encircling ligands with two FSTL3 molecules to block all receptor-binding sites (established by 2.5 Å crystal structure); unlike follistatin, FSTL3 lacks a heparin-binding sequence and thus does not associate with cell surfaces, conferring distinct tissue-level bioavailability. Its transcription is induced by TGF-β and activin A via Smad3/4-binding elements, and by TNF-α via NF-κB, creating a negative feedback loop that limits activin signaling. In vivo, FSTL3 antagonism of activin regulates pancreatic beta-cell mass, visceral fat, glucose homeostasis, and testicular size/aging; it also has intranuclear functions enhancing AF10-mediated transcription, and in cancer contexts can stabilize c-Myc to promote immune evasion, bind TfR1 to activate AKT/mTOR for vasculogenic mimicry, and regulate cuproptosis susceptibility through the SLC25A10/succinate/DLAT axis."},"narrative":{"mechanistic_narrative":"FSTL3 is a secreted follistatin-family glycoprotein that functions as an extracellular antagonist of TGF-β superfamily ligands, principally activin A, restraining activin/Smad signaling across reproductive and metabolic tissues [PMID:9671416, PMID:11451569, PMID:17671190]. It binds activin with affinity and selectivity comparable to follistatin but, unlike follistatin, lacks a heparin-binding sequence and therefore does not associate with cell surfaces, conferring distinct tissue-level bioavailability [PMID:11451569, PMID:15471966]. The 2.5 Å crystal structure of the FSTL3–activin A complex shows two FSTL3 molecules encircling the ligand to occlude all receptor-binding sites, with the FSTL3 N-terminal domain making intimate contacts that explain its activin specificity [PMID:18768470]. FSTL3 transcription is induced by TGF-β and activin A through Smad3/Smad4 binding to a Smad-binding element in its promoter, and by TNF-α through NF-κB elements, with TGF-β potentiating the TNF-α response—establishing a negative feedback loop that limits activin signaling [PMID:11571638, PMID:11948405, PMID:17395406]. In vivo, loss of FSTL3 releases activin and myostatin bioactivity, producing pancreatic islet and beta-cell hyperplasia, increased α-to-β cell transdifferentiation, reduced visceral fat, improved glucose tolerance, and enlarged testes with delayed age-related regression [PMID:17229845, PMID:26727106, PMID:23407452]. Beyond ligand sequestration, FSTL3 has an intranuclear role enhancing AF10 oligomerization and AF10-mediated transcription [PMID:17868029], and in cancer it acts through activin-independent routes—stabilizing c-Myc to promote immune evasion [PMID:38302412], binding transferrin receptor TfR1 to activate AKT/mTOR and drive vasculogenic mimicry [PMID:41053124], and modulating the SLC25A10/succinate/DLAT axis to govern cuproptosis susceptibility [PMID:41996175].","teleology":[{"year":1998,"claim":"Identification of FSTL3 from a leukemia-associated chromosomal translocation established it as a novel secreted member of the follistatin family, framing later questions about its ligand-binding function.","evidence":"cDNA cloning and molecular characterization of a t(11;19) translocation in B-cell CLL","pmids":["9671416"],"confidence":"Medium","gaps":["No ligand or binding partner identified at cloning stage","Functional role of the translocation unresolved"]},{"year":2001,"claim":"Demonstrating that FSTL3 binds activin and is itself induced by TGF-β/activin via direct Smad3/4 promoter binding defined it as a transcriptionally regulated activin antagonist within a feedback loop.","evidence":"Immunoprecipitation/Far-Western binding assays, promoter reporter with deletion/point mutagenesis, dominant-negative Smad, and EMSA","pmids":["11274757","11451569","11571638"],"confidence":"High","gaps":["Quantitative ligand selectivity across activin isoforms not yet resolved","Structural basis of antagonism unknown"]},{"year":2002,"claim":"Showing FSTL3 blocks activin-induced gene transcription and growth inhibition while being activin-inducible closed the negative feedback loop functionally.","evidence":"Transcriptional reporter and HepG2 growth-inhibition assays with phospho-Smad2 readout","pmids":["11948405"],"confidence":"High","gaps":["In vivo relevance of feedback not yet tested","Ligand specificity beyond activin A not addressed"]},{"year":2003,"claim":"Quantifying differential binding and neutralization of activin A versus activin B established FSTL3 as a ligand-selective antagonist rather than a pan-activin sink.","evidence":"Binding assays and 293-cell neutralization reporter assays","pmids":["12697670"],"confidence":"Medium","gaps":["Structural basis of isoform discrimination not defined","Selectivity against other TGF-β ligands untested here"]},{"year":2004,"claim":"Mapping the absence of a heparin-binding sequence and the trade-off between heparin and activin binding explained why FSTL3, unlike follistatin, does not bind cell surfaces, distinguishing their bioavailability.","evidence":"Domain-insertion mutagenesis with heparin affinity, cell-surface binding, activin binding, and pituitary FSH bioassay","pmids":["15471966"],"confidence":"High","gaps":["Physiological consequence of non-surface localization not directly tested","Whether soluble distribution alters tissue targeting unmeasured"]},{"year":2005,"claim":"Discovery of direct interactions with fibronectin and ADAM12, with functional effects on hematopoietic adhesion and osteoclast differentiation, extended FSTL3's roles beyond soluble ligand antagonism into matrix and cellular contexts.","evidence":"Yeast two-hybrid, co-IP/pulldown, cell adhesion assays, and osteoclast differentiation assays","pmids":["16336961","15574124"],"confidence":"Medium","gaps":["Mechanistic link between these interactions and activin biology unclear","Single-lab interactions without reciprocal in vivo validation"]},{"year":2007,"claim":"Showing TNF-α drives FSTL3 transcription via NF-κB, with TGF-β/Smad potentiation, integrated inflammatory signaling into the control of FSTL3 expression.","evidence":"Promoter deletion/reporter analysis, phylogenetic footprinting, and NF-κB binding assays","pmids":["17395406"],"confidence":"Medium","gaps":["Physiological context of TNF-α induction not established","Cross-talk between NF-κB and Smad inputs in vivo untested"]},{"year":2007,"claim":"Knockout mice and breast cancer knockdown placed FSTL3 antagonism of activin/myostatin causally upstream of beta-cell mass, glucose homeostasis, visceral fat, and tumor proliferation.","evidence":"Homozygous FSTL3 knockout metabolic phenotyping and siRNA silencing with activin-receptor rescue in breast cancer cells","pmids":["17229845","17671190"],"confidence":"High","gaps":["Tissue-specific contributions not dissected","Distinguishing activin- versus myostatin-driven phenotypes incomplete"]},{"year":2007,"claim":"Identifying nuclear FSTL3 interaction with AF10 and enhancement of its transcriptional activity revealed an intranuclear function distinct from secreted ligand antagonism.","evidence":"Yeast two-hybrid, Far-Western, co-IP in COS-7, oligomerization, and Gal4 transactivation assays","pmids":["17868029"],"confidence":"Medium","gaps":["Mechanism of nuclear entry for a secreted protein unexplained","Endogenous chromatin targets of FSTL3/AF10 unknown"]},{"year":2008,"claim":"The crystal structure of the FSTL3–activin A complex defined the molecular mechanism of antagonism—two FSTL3 molecules encircling the ligand to block all receptor sites—and the N-terminal domain basis of specificity.","evidence":"2.5 Å X-ray crystallography with domain-swap binding studies","pmids":["18768470"],"confidence":"High","gaps":["Structures with other ligands (activin B, myostatin) not solved","Conformational dynamics in solution not addressed"]},{"year":2016,"claim":"Lineage tracing showing increased α-to-β cell transdifferentiation in knockouts, reproduced by activin treatment, identified a cell-fate mechanism underlying FSTL3's control of beta-cell mass.","evidence":"Gluc-Cre/YFP lineage tracing, flow cytometry, and activin treatment of isolated islets","pmids":["26727106"],"confidence":"High","gaps":["Human relevance of transdifferentiation not established","Downstream beta-cell maturation program undefined"]},{"year":2013,"claim":"Testicular enlargement and delayed aging in knockouts, with elevated AKT/SIRT1 signaling, linked FSTL3 ligand antagonism to AKT pathway cross-talk in reproductive tissue.","evidence":"FSTL3 knockout histomorphometry and western blot for AKT/SIRT1","pmids":["23407452"],"confidence":"Medium","gaps":["Direct mechanistic connection between activin release and AKT activation unproven","Single-model finding"]},{"year":2021,"claim":"Discovery that FSTL3 stabilizes c-Myc by suppressing its ubiquitination to upregulate PDL1/IDO1, plus a selective neutralizing antibody enhancing islet insulin secretion, revealed activin-independent oncogenic activity and therapeutic targetability.","evidence":"Co-IP with domain mapping, ubiquitination assays, FSTL3-knockout immunocompetent tumor models, and FP-101 neutralizing antibody islet assays","pmids":["38302412","33539535"],"confidence":"Medium","gaps":["How secreted FSTL3 accesses cytoplasmic/nuclear c-Myc unresolved","Antibody efficacy in vivo for diabetes not yet established"]},{"year":2024,"claim":"Mapping KDM1B-driven H3K9me2 loss at the FSTL3 promoter under prenatal dexamethasone defined an epigenetic route to FSTL3 upregulation that impairs blood-testis barrier function via reduced TGF-β signaling.","evidence":"ChIP for H3K9me2, dexamethasone treatment of Sertoli cells, and in vivo rat model","pmids":["38472317"],"confidence":"Medium","gaps":["Generalizability beyond dexamethasone exposure unknown","Human translation untested"]},{"year":2025,"claim":"Multiple cancer studies established new activin-independent FSTL3 axes—TfR1/AKT/mTOR-driven vasculogenic mimicry, SLC25A10/succinate/DLAT-controlled cuproptosis, and ZNF454-repressed HIF-1α glycolysis—broadening its role in tumor metabolism and metastasis.","evidence":"Co-IP/binding assays, scRNA-seq, CRISPR screens, metabolomics/succinylation assays, ChIP/luciferase, and in vivo metastasis/xenograft models with antibody neutralization","pmids":["41053124","41996175","41522747"],"confidence":"Medium","gaps":["Whether these axes operate through the same secreted FSTL3 pool is unclear","Interplay between activin-dependent and activin-independent functions undefined"]},{"year":null,"claim":"It remains unresolved how a secreted activin antagonist accesses intracellular and nuclear targets (c-Myc, AF10) and whether its diverse cancer-associated metabolic and signaling functions share a unifying mechanism.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No mechanism for cellular re-entry or nuclear localization of secreted FSTL3","Integration of activin-dependent and activin-independent roles not established","Structural basis of TfR1 and c-Myc binding undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,4,11,13]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[13,6]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[12]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,2,6]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[12]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[7]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,11,3]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[10,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[17,20,21]}],"complexes":[],"partners":["INHBA","FN1","ADAM12","AF10","MYC","TFRC","SLC25A10"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95633","full_name":"Follistatin-related protein 3","aliases":["Follistatin-like protein 3","Follistatin-related gene protein"],"length_aa":263,"mass_kda":27.7,"function":"Isoform 1 or the secreted form is a binding and antagonizing protein for members of the TGF-beta family, such as activin, BMP2 and MSTN. Inhibits activin A-, activin B-, BMP2- and MSDT-induced cellular signaling; more effective on activin A than on activin B. Involved in bone formation; inhibits osteoclast differentiation. Involved in hematopoiesis; involved in differentiation of hemopoietic progenitor cells, increases hematopoietic cell adhesion to fibronectin and seems to contribute to the adhesion of hematopoietic precursor cells to the bone marrow stroma. Isoform 2 or the nuclear form is probably involved in transcriptional regulation via interaction with MLLT10","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/O95633/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FSTL3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FSTL3","total_profiled":1310},"omim":[{"mim_id":"605343","title":"FOLLISTATIN-LIKE 3; FSTL3","url":"https://www.omim.org/entry/605343"},{"mim_id":"168461","title":"CYCLIN D1; CCND1","url":"https://www.omim.org/entry/168461"},{"mim_id":"136470","title":"FOLLISTATIN; FST","url":"https://www.omim.org/entry/136470"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/FSTL3"},"hgnc":{"alias_symbol":["FLRG","FSRP"],"prev_symbol":[]},"alphafold":{"accession":"O95633","domains":[{"cath_id":"3.90.290.10","chopping":"35-93","consensus_level":"high","plddt":89.2995,"start":35,"end":93},{"cath_id":"3.30.60.30","chopping":"180-239","consensus_level":"medium","plddt":97.3548,"start":180,"end":239}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95633","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95633-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95633-F1-predicted_aligned_error_v6.png","plddt_mean":85.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FSTL3","jax_strain_url":"https://www.jax.org/strain/search?query=FSTL3"},"sequence":{"accession":"O95633","fasta_url":"https://rest.uniprot.org/uniprotkb/O95633.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95633/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95633"}},"corpus_meta":[{"pmid":"17229845","id":"PMC_17229845","title":"FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults.","date":"2007","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/17229845","citation_count":135,"is_preprint":false},{"pmid":"9671416","id":"PMC_9671416","title":"FLRG (follistatin-related gene), a new target of chromosomal rearrangement in malignant blood disorders.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9671416","citation_count":104,"is_preprint":false},{"pmid":"11948405","id":"PMC_11948405","title":"Transcription activation of FLRG and follistatin by activin A, through Smad proteins, participates in a negative feedback loop to modulate activin A function.","date":"2002","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11948405","citation_count":79,"is_preprint":false},{"pmid":"12697670","id":"PMC_12697670","title":"Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG).","date":"2003","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12697670","citation_count":63,"is_preprint":false},{"pmid":"17671190","id":"PMC_17671190","title":"Silencing of FLRG, an antagonist of activin, inhibits human breast tumor cell growth.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17671190","citation_count":61,"is_preprint":false},{"pmid":"18768470","id":"PMC_18768470","title":"The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18768470","citation_count":60,"is_preprint":false},{"pmid":"11451569","id":"PMC_11451569","title":"Follistatin-related protein (FSRP): a new member of the follistatin gene family.","date":"2001","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11451569","citation_count":56,"is_preprint":false},{"pmid":"11274757","id":"PMC_11274757","title":"Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected].","date":"2001","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11274757","citation_count":41,"is_preprint":false},{"pmid":"15471966","id":"PMC_15471966","title":"Heparin and activin-binding determinants in follistatin and FSTL3.","date":"2004","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15471966","citation_count":40,"is_preprint":false},{"pmid":"19740438","id":"PMC_19740438","title":"Differential expression of follistatin and FLRG in human breast proliferative disorders.","date":"2009","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19740438","citation_count":39,"is_preprint":false},{"pmid":"11571638","id":"PMC_11571638","title":"FLRG, an activin-binding protein, is a new target of TGFbeta transcription activation through Smad proteins.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11571638","citation_count":37,"is_preprint":false},{"pmid":"32280246","id":"PMC_32280246","title":"Up-Regulation of FSTL3, Regulated by lncRNA DSCAM-AS1/miR-122-5p Axis, Promotes Proliferation and Migration of Non-Small Cell Lung Cancer Cells.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32280246","citation_count":35,"is_preprint":false},{"pmid":"15451575","id":"PMC_15451575","title":"FLRG, member of the follistatin family, a new player in hematopoiesis.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15451575","citation_count":33,"is_preprint":false},{"pmid":"23407452","id":"PMC_23407452","title":"Follistatin-like 3 (FSTL3) mediated silencing of transforming growth factor β (TGFβ) signaling is essential for testicular aging and regulating testis size.","date":"2013","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/23407452","citation_count":32,"is_preprint":false},{"pmid":"28339962","id":"PMC_28339962","title":"FSTL3 is increased in renal dysfunction.","date":"2017","source":"Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association","url":"https://pubmed.ncbi.nlm.nih.gov/28339962","citation_count":24,"is_preprint":false},{"pmid":"17395406","id":"PMC_17395406","title":"Identification of NF-kappaB responsive elements in follistatin related gene (FLRG) promoter.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17395406","citation_count":24,"is_preprint":false},{"pmid":"16336961","id":"PMC_16336961","title":"A novel role for fibronectin type I domain in the regulation of human hematopoietic cell adhesiveness through binding to follistatin domains of FLRG and follistatin.","date":"2005","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/16336961","citation_count":22,"is_preprint":false},{"pmid":"15574124","id":"PMC_15574124","title":"FLRG, a new ADAM12-associated protein, modulates osteoclast differentiation.","date":"2005","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15574124","citation_count":22,"is_preprint":false},{"pmid":"15130517","id":"PMC_15130517","title":"Human endometrium and decidua express follistatin-related gene (FLRG) mRNA and peptide.","date":"2004","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/15130517","citation_count":21,"is_preprint":false},{"pmid":"12970321","id":"PMC_12970321","title":"Follistatin-related gene (FLRG) expression in human endometrium: sex steroid hormones regulate the expression of FLRG in cultured human endometrial stromal cells.","date":"2003","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12970321","citation_count":19,"is_preprint":false},{"pmid":"38302412","id":"PMC_38302412","title":"FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38302412","citation_count":18,"is_preprint":false},{"pmid":"31815869","id":"PMC_31815869","title":"FSTL3 Induces Lipid Accumulation and Inflammatory Response in Macrophages and Associates With Atherosclerosis.","date":"2019","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31815869","citation_count":16,"is_preprint":false},{"pmid":"26727106","id":"PMC_26727106","title":"Activin Enhances α- to β-Cell Transdifferentiation as a Source For β-Cells In Male FSTL3 Knockout Mice.","date":"2016","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/26727106","citation_count":16,"is_preprint":false},{"pmid":"12397211","id":"PMC_12397211","title":"Regulation of follistatin-related gene (FLRG) expression by protein kinase C and prostaglandin E(2) in cultured granulosa-luteal cells.","date":"2002","source":"Molecular human reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/12397211","citation_count":15,"is_preprint":false},{"pmid":"12645077","id":"PMC_12645077","title":"Regulation of FLRG expression in rat primary astroglial cells and injured brain tissue by transforming growth factor-beta 1 (TGF-beta 1).","date":"2003","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/12645077","citation_count":14,"is_preprint":false},{"pmid":"36502285","id":"PMC_36502285","title":"FSTL3 is highly expressed in adipose tissue of individuals with overweight or obesity and is associated with inflammation.","date":"2022","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/36502285","citation_count":13,"is_preprint":false},{"pmid":"23022195","id":"PMC_23022195","title":"Synexpression group analyses identify new functions of FSTL3, a TGFβ ligand inhibitor.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/23022195","citation_count":12,"is_preprint":false},{"pmid":"34901156","id":"PMC_34901156","title":"Bioinformatic Analyses and Experimental Verification Reveal that High FSTL3 Expression Promotes EMT via Fibronectin-1/α5β1 Interaction in Colorectal Cancer.","date":"2021","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/34901156","citation_count":12,"is_preprint":false},{"pmid":"17868029","id":"PMC_17868029","title":"AF10-dependent transcription is enhanced by its interaction with FLRG.","date":"2007","source":"Biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17868029","citation_count":11,"is_preprint":false},{"pmid":"37904173","id":"PMC_37904173","title":"FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus.","date":"2023","source":"Cardiovascular diabetology","url":"https://pubmed.ncbi.nlm.nih.gov/37904173","citation_count":9,"is_preprint":false},{"pmid":"34723652","id":"PMC_34723652","title":"The Activin/FLRG Pathway Associates with Poor COVID-19 Outcomes in Hospitalized Patients.","date":"2021","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34723652","citation_count":8,"is_preprint":false},{"pmid":"34858481","id":"PMC_34858481","title":"LBX2-AS1 Activates FSTL3 by Binding to Transcription Factor RARα to Foster Proliferation, Migration, and Invasion of Thyroid Cancer.","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34858481","citation_count":8,"is_preprint":false},{"pmid":"12039070","id":"PMC_12039070","title":"Genomic organization and promoter analysis of mouse follistatin-related gene (FLRG).","date":"2002","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/12039070","citation_count":7,"is_preprint":false},{"pmid":"34555811","id":"PMC_34555811","title":"Inhibition of FSTL3 abates the proliferation and metastasis of renal cell carcinoma via the GSK-3β/β-catenin signaling pathway.","date":"2021","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/34555811","citation_count":7,"is_preprint":false},{"pmid":"16737827","id":"PMC_16737827","title":"Purification of recombinant activin A using the second follistatin domain of follistatin-related gene (FLRG).","date":"2006","source":"Protein expression and purification","url":"https://pubmed.ncbi.nlm.nih.gov/16737827","citation_count":6,"is_preprint":false},{"pmid":"33539535","id":"PMC_33539535","title":"FSTL3-Neutralizing Antibodies Enhance Glucose-Responsive Insulin Secretion in Dysfunctional Male Mouse and Human Islets.","date":"2021","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/33539535","citation_count":4,"is_preprint":false},{"pmid":"40140870","id":"PMC_40140870","title":"Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis.","date":"2025","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/40140870","citation_count":4,"is_preprint":false},{"pmid":"29482497","id":"PMC_29482497","title":"Uteroglobin and FLRG concentrations in aqueous humor are associated with age in primary open angle glaucoma patients.","date":"2018","source":"BMC ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/29482497","citation_count":4,"is_preprint":false},{"pmid":"33314336","id":"PMC_33314336","title":"Expression and functional analysis of the Follistatin-like 3 (FSTL3) gene in the sheep ovary during the oestrous cycle.","date":"2020","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/33314336","citation_count":3,"is_preprint":false},{"pmid":"40154584","id":"PMC_40154584","title":"FSTL3 promotes colorectal cancer by activating the HIF1 pathway.","date":"2025","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/40154584","citation_count":2,"is_preprint":false},{"pmid":"14692692","id":"PMC_14692692","title":"Purification, cDNA cloning, and secretory properties of FLRG protein from PC12 cells and the distribution of FLRG mRNA and protein in rat tissues.","date":"2003","source":"Archives of histology and cytology","url":"https://pubmed.ncbi.nlm.nih.gov/14692692","citation_count":2,"is_preprint":false},{"pmid":"38472317","id":"PMC_38472317","title":"Prenatal dexamethasone exposure impairs rat blood-testis barrier function and sperm quality in adult offspring via GR/KDM1B/FSTL3/TGFβ signaling.","date":"2024","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/38472317","citation_count":2,"is_preprint":false},{"pmid":"41053124","id":"PMC_41053124","title":"Cancer-associated fibroblasts expressing FSTL3 promote vasculogenic mimicry formation and drive colon cancer malignancy.","date":"2025","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/41053124","citation_count":1,"is_preprint":false},{"pmid":"38044354","id":"PMC_38044354","title":"Stroma-associated FSTL3 is a factor of calcium channel-derived tumor fibrosis.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38044354","citation_count":1,"is_preprint":false},{"pmid":"30756375","id":"PMC_30756375","title":"Gene structure, recombinant expression and function characterization of Siniperca chuatsi Fsrp-3.","date":"2019","source":"Journal of fish biology","url":"https://pubmed.ncbi.nlm.nih.gov/30756375","citation_count":0,"is_preprint":false},{"pmid":"41522747","id":"PMC_41522747","title":"ZNF454-FSTL3 axis inhibits colorectal cancer progression by inhibiting HIF-1α-mediated glycolysis in hypoxia.","date":"2025","source":"Journal of gastrointestinal oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41522747","citation_count":0,"is_preprint":false},{"pmid":"41996175","id":"PMC_41996175","title":"FSTL3-Driven Cuproptosis Resistance and EPCs Promote OSCC Metastasis.","date":"2026","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/41996175","citation_count":0,"is_preprint":false},{"pmid":"41871850","id":"PMC_41871850","title":"Cinnamaldehyde Regulates the EMT Process and Drug Resistance of Gastric Cancer Through FSTL3-Mediated Cytoskeletal Remodeling.","date":"2026","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/41871850","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.06.25323530","title":"Plasma Levels of Activin A and Follistatin-Like-3 as Biomarkers for Pulmonary Hypertension in Advanced Heart Failure","date":"2025-03-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.06.25323530","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.13.24317296","title":"Higher burden of cerebral small vessel disease is associated with risk of incident stroke in community dwelling individuals","date":"2024-11-15","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.13.24317296","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.03.611067","title":"Placental Network Differences Among Obstetric Syndromes Identified With An Integrated Multiomics Approach","date":"2024-09-07","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.03.611067","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":28427,"output_tokens":5707,"usd":0.085443,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14248,"output_tokens":4900,"usd":0.09687,"stage2_stop_reason":"end_turn"},"total_usd":0.182313,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"FSTL3 (FLRG) encodes a secreted glycoprotein belonging to the follistatin-module-protein family, identified from a chromosomal translocation t(11;19)(q13;p13) in B-cell chronic lymphocytic leukemia, establishing it as a novel secreted protein of the follistatin family.\",\n      \"method\": \"cDNA cloning and molecular characterization of chromosomal translocation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — molecular cloning with sequence analysis and expression studies, single lab but foundational characterization\",\n      \"pmids\": [\"9671416\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FSTL3 (FLRG) binds activin A, as demonstrated by immunoprecipitation and Far-Western blot analysis, and its expression in bone marrow stromal cells is dramatically upregulated by TGF-β at both mRNA and protein levels.\",\n      \"method\": \"Immunoprecipitation, Far-Western blot, RT-PCR, Northern blot\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding assays (IP and Far-Western), single lab, two orthogonal methods\",\n      \"pmids\": [\"11274757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FSTL3 (FSRP) binds activin with similar affinity and selectivity as follistatin but does not bind heparin. FSTL3 inhibits activin-mediated gene transcription in heterologous assays but is much less active than follistatin in the rat pituitary bioassay. Overexpression in transgenic mice disrupts follicular development and fertility in females.\",\n      \"method\": \"Binding assays, transcriptional reporter assay, pituitary bioassay, transgenic mouse overexpression\",\n      \"journal\": \"Molecular and cellular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods (binding, reporter, bioassay, transgenic), single lab\",\n      \"pmids\": [\"11451569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TGF-β induces FSTL3 (FLRG) transcription through Smad proteins binding to a Smad-binding element in the FLRG promoter. Dominant-negative Smad3 and Smad4 mutants block TGF-β-induced transactivation. Smad3 and Smad4 proteins directly bind the SBE motif in the FLRG promoter as shown by EMSA.\",\n      \"method\": \"Promoter reporter assay, deletion/point-mutation analysis, dominant-negative Smad transfection, EMSA (gel shift)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — promoter mutagenesis, dominant-negative functional validation, and direct DNA-binding EMSA in one study; mechanistic detail replicated in follow-up papers\",\n      \"pmids\": [\"11571638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"FSTL3 (FLRG) protein inhibits activin A signaling in transcriptional reporter assays and blocks activin A-induced growth inhibition of HepG2 cells. Activin A induces FSTL3 and follistatin expression via Smad proteins, and FSTL3 protein in turn regulates its own activin-induced expression, constituting a negative feedback loop.\",\n      \"method\": \"Transcriptional reporter assay, cell growth assay, phospho-Smad2 analysis, Smad transfection\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (reporter, growth inhibition, feedback regulation), replicated Smad mechanism from prior work, two independent labs\",\n      \"pmids\": [\"11948405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"FSTL3 binds activin B approximately 10-fold less potently than activin A, and is approximately 3-fold more effective in neutralizing activin A relative to activin B in reporter assays, demonstrating differential binding and neutralization specificity.\",\n      \"method\": \"Binding assays, 293 cell reporter assays for neutralization\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative binding and functional neutralization assays, single lab, two orthogonal methods\",\n      \"pmids\": [\"12697670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FSTL3 lacks a heparin-binding sequence and cannot associate with cell surfaces or heparin, unlike follistatin. Insertion of the full follistatin domain 1 (containing the HBS) into FSTL3 conferred heparin binding but abolished activin binding, implying an evolutionary safeguard against surface binding by FSTL3.\",\n      \"method\": \"Mutational analysis, cell surface binding assay, heparin affinity binding, competitive activin binding, pituitary cell FSH secretion bioassay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — systematic mutagenesis with multiple functional readouts (heparin binding, cell surface binding, activin binding, bioassay), single lab but multiple orthogonal methods\",\n      \"pmids\": [\"15471966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FSTL3 (FLRG) physically interacts with human fibronectin; the interaction is mediated by type I motifs of fibronectin and follistatin domains of FSTL3/follistatin. This interaction increases adhesion of hematopoietic cells to fibronectin in a dose-dependent manner, including immature hematopoietic precursors (CFC, LTC-IC).\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation/pulldown, cell adhesion assay with primary hematopoietic cells and cell lines\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus functional adhesion assay, single lab, two orthogonal methods\",\n      \"pmids\": [\"16336961\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"FSTL3 (FLRG) directly interacts with ADAM12 via its cysteine-rich domain, as identified by yeast two-hybrid and confirmed by direct interaction assay. FSTL3 protein inhibits osteoclast differentiation from murine primary spleen cells and RAW264.7 macrophages stimulated with RANK-L and M-CSF, reducing osteoclast number and nuclei per osteoclast.\",\n      \"method\": \"Yeast two-hybrid screen, direct protein interaction assay, osteoclast differentiation assay (primary spleen cells and RAW264.7 cells)\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid plus functional cellular assay with primary cells, single lab, two orthogonal methods\",\n      \"pmids\": [\"15574124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"TNF-α activates FSTL3 (FLRG) transcription through NF-κB binding to four tandem 107-108 bp DNA repeats in the FLRG promoter, each containing an NF-κB responsive element (5'-GGGAGAG/TTCC-3'). TGF-β through Smad proteins potentiates TNF-α-induced FSTL3 expression.\",\n      \"method\": \"Promoter reporter assay, deletion analysis, phylogenetic footprinting, NF-κB binding assay\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter deletion analysis with functional reporter assay and binding studies, single lab\",\n      \"pmids\": [\"17395406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FSTL3 knockout adult mice develop increased pancreatic islet number and size, beta cell hyperplasia, decreased visceral fat mass, improved glucose tolerance, and enhanced insulin sensitivity, attributable to increased activin and myostatin bioactivity in specific tissues in the absence of the FSTL3 antagonist.\",\n      \"method\": \"Homozygous FSTL3 knockout mouse model with metabolic phenotyping (glucose tolerance, insulin sensitivity, histomorphometry)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean KO with multiple defined metabolic phenotypes and mechanistic attribution to activin/myostatin signaling, multiple phenotypic readouts\",\n      \"pmids\": [\"17229845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"FSTL3 (FLRG) silencing in breast cancer cell lines restores endogenous activin signaling (increased phospho-Smad2 and activin target gene transcripts), causes growth inhibition reversible by exogenous FSTL3 or soluble type II activin receptor, demonstrating FSTL3 promotes tumor cell proliferation by antagonizing endogenous activin.\",\n      \"method\": \"siRNA silencing, phospho-Smad2 western blot, gene expression analysis, cell growth assay, receptor rescue experiment\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — loss-of-function with multiple mechanistic readouts (signaling, rescue), defined pathway placement via activin receptor rescue\",\n      \"pmids\": [\"17671190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Nuclear FSTL3 (FLRG) interacts with AF10 (MLL fusion partner) via AF10's N-terminal PHD domain. FSTL3 enhances AF10 homo-oligomerization and increases AF10-mediated transcriptional activation in transient transfection assays, revealing an intranuclear transcriptional co-regulatory function.\",\n      \"method\": \"Yeast two-hybrid, Far-Western blot, co-immunoprecipitation in COS-7 cells, oligomerization assay, Gal4-fusion transactivation assay\",\n      \"journal\": \"Biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple binding assays (Y2H, Far-Western, Co-IP) plus functional transcription assay, single lab\",\n      \"pmids\": [\"17868029\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"X-ray crystal structure of FSTL3 in complex with activin A (2.5 Å resolution) shows two FSTL3 molecules encircling the ligand and blocking all receptor-binding sites. The FSTL3 N-terminal domain makes more intimate contact with activin A than the corresponding follistatin domain, and replacing the FSTL3 N-terminal domain with the follistatin N-terminal domain considerably lowers activin A affinity, explaining FSTL3's specificity.\",\n      \"method\": \"X-ray crystallography, domain-swap binding studies\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — high-resolution crystal structure combined with biochemical mutagenesis/domain-swap validation, mechanistic detail at atomic resolution\",\n      \"pmids\": [\"18768470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FSTL3 knockout mice develop markedly enlarged testes with increased Sertoli cell numbers and enhanced spermatogenesis, and show delayed age-related testicular regression. FSTL3 deletion leads to increased AKT signaling and SIRT1 expression in the testis, demonstrating cross-talk between TGF-β ligand and AKT signaling pathways.\",\n      \"method\": \"FSTL3 knockout mouse model, histomorphometry, western blot for AKT/SIRT1 signaling\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO model with defined cellular phenotype and signaling pathway analysis, single lab\",\n      \"pmids\": [\"23407452\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In FSTL3 knockout mice, α-to-β cell transdifferentiation is increased, as demonstrated by Gluc-Cre/YFP lineage tracing showing significantly more Ins+/YFP+ cells versus wild-type. Activin treatment of isolated islets significantly increased YFP+/Ins+ cells, demonstrating that activin signaling (released from FSTL3 antagonism) drives this transdifferentiation.\",\n      \"method\": \"Gluc-Cre/YFP α-cell lineage tracing, flow cytometry, fluorescent cell counting in pancreatic sections, activin treatment of isolated islets\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic lineage tracing with flow cytometry and histological confirmation, plus pharmacological activin treatment, multiple orthogonal methods\",\n      \"pmids\": [\"26727106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"FSTL3 promotes lipid accumulation in macrophages and upregulates scavenger receptors CD36 and LOX-1 in a dose-dependent manner. FSTL3 also induces secretion of inflammatory cytokines (IL-1β, MCP-1, TNF-α, MMP-9) in macrophages. Oxidized LDL induces FSTL3 expression and secretion.\",\n      \"method\": \"Cell treatment assays, western blot for CD36/LOX-1, ELISA for cytokines, lipid accumulation assay, FSTL3 knockdown\",\n      \"journal\": \"Journal of cardiovascular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dose-dependent functional assays with knockdown controls, single lab\",\n      \"pmids\": [\"31815869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FSTL3 binds to transcription factor c-Myc (at amino acids 354–406), suppresses c-Myc ubiquitination and increases its stability, thereby upregulating PDL1 and IDO1 expression to promote tumor immune evasion in colorectal cancer. FSTL3 expression in CRC cells is induced by hypoxia via HIF1α.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, western blot, FSTL3 knockout immunocompetent tumor models, flow cytometry for immune cell populations\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP with specific domain mapping (aa354-406), ubiquitination assay, in vivo KO model with immune phenotyping, single lab\",\n      \"pmids\": [\"38302412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"An FSTL3-neutralizing antibody (FP-101) that selectively disrupts FSTL3-activin complexes (without affecting follistatin) enhances glucose-responsive insulin secretion from dysfunctional mouse and human islets in vitro under conditions modeling diabetes.\",\n      \"method\": \"Neutralizing antibody development, in vitro activin-complex disruption assay, insulin secretion assay from mouse and human islets\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological neutralization with selectivity characterization and functional islet readout, single lab\",\n      \"pmids\": [\"33539535\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Prenatal dexamethasone exposure increases KDM1B expression in fetal testicular Sertoli cells, which decreases H3K9me2 levels at the FSTL3 promoter, thereby epigenetically upregulating FSTL3 expression. Increased FSTL3 inhibits TGF-β signaling and reduces CX43/E-cadherin expression, impairing blood-testis barrier function and sperm quality.\",\n      \"method\": \"ChIP for H3K9me2 at FSTL3 promoter, western blot, dexamethasone treatment of TM4 Sertoli cells, in vivo rat model\",\n      \"journal\": \"Acta pharmacologica Sinica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating epigenetic regulation of FSTL3 promoter with functional consequence in Sertoli cells, validated in vivo and in vitro, single lab\",\n      \"pmids\": [\"38472317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FSTL3 expressed by cancer-associated fibroblasts binds to transferrin receptor (TfR1) on cancer cells, activating the TfR1/AKT/mTOR pathway and elevating VE-Cadherin to support endothelial-like transformation, vasculogenic mimicry, and metastatic progression in colon cancer. FSTL3-targeting antibodies inhibited vasculogenic mimicry and synergized with bevacizumab.\",\n      \"method\": \"Co-immunoprecipitation/binding assay, single-cell RNA sequencing, in vitro and in vivo functional assays, antibody neutralization\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding interaction with functional pathway activation demonstrated in vitro and in vivo, single lab\",\n      \"pmids\": [\"41053124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FSTL3 loss in OSCC cells induces cuproptosis susceptibility by suppressing SLC25A10, leading to mitochondrial succinate accumulation, succinate-driven succinylation and upregulation of DLAT (essential for cuproptosis execution), thereby suppressing lymph node metastasis.\",\n      \"method\": \"CRISPR-Cas9 screening, knockdown studies, metabolomics for succinate, succinylation assay, in vivo metastasis models\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen followed by mechanistic validation of SLC25A10/succinate/DLAT axis, single lab, multiple methods\",\n      \"pmids\": [\"41996175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZNF454 binds directly to the FSTL3 promoter (confirmed by ChIP and dual-luciferase assay) and transcriptionally represses FSTL3, which in turn suppresses HIF-1α-mediated glycolysis in colorectal cancer cells under hypoxic conditions. FSTL3 overexpression reverses ZNF454-mediated suppression of proliferation, migration, invasion, and glycolysis.\",\n      \"method\": \"ChIP assay, dual-luciferase reporter assay, RT-qPCR, western blot, metabolic flux assays (ECAR/OCR), in vivo xenograft\",\n      \"journal\": \"Journal of gastrointestinal oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and luciferase with functional rescue experiments, single lab\",\n      \"pmids\": [\"41522747\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FSTL3 is a secreted glycoprotein that acts as an extracellular antagonist of TGF-β superfamily ligands (primarily activin A, activin B, and myostatin) by encircling ligands with two FSTL3 molecules to block all receptor-binding sites (established by 2.5 Å crystal structure); unlike follistatin, FSTL3 lacks a heparin-binding sequence and thus does not associate with cell surfaces, conferring distinct tissue-level bioavailability. Its transcription is induced by TGF-β and activin A via Smad3/4-binding elements, and by TNF-α via NF-κB, creating a negative feedback loop that limits activin signaling. In vivo, FSTL3 antagonism of activin regulates pancreatic beta-cell mass, visceral fat, glucose homeostasis, and testicular size/aging; it also has intranuclear functions enhancing AF10-mediated transcription, and in cancer contexts can stabilize c-Myc to promote immune evasion, bind TfR1 to activate AKT/mTOR for vasculogenic mimicry, and regulate cuproptosis susceptibility through the SLC25A10/succinate/DLAT axis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FSTL3 is a secreted follistatin-family glycoprotein that functions as an extracellular antagonist of TGF-\\u03b2 superfamily ligands, principally activin A, restraining activin/Smad signaling across reproductive and metabolic tissues [#0, #2, #11]. It binds activin with affinity and selectivity comparable to follistatin but, unlike follistatin, lacks a heparin-binding sequence and therefore does not associate with cell surfaces, conferring distinct tissue-level bioavailability [#2, #6]. The 2.5 \\u00c5 crystal structure of the FSTL3\\u2013activin A complex shows two FSTL3 molecules encircling the ligand to occlude all receptor-binding sites, with the FSTL3 N-terminal domain making intimate contacts that explain its activin specificity [#13]. FSTL3 transcription is induced by TGF-\\u03b2 and activin A through Smad3/Smad4 binding to a Smad-binding element in its promoter, and by TNF-\\u03b1 through NF-\\u03baB elements, with TGF-\\u03b2 potentiating the TNF-\\u03b1 response\\u2014establishing a negative feedback loop that limits activin signaling [#3, #4, #9]. In vivo, loss of FSTL3 releases activin and myostatin bioactivity, producing pancreatic islet and beta-cell hyperplasia, increased \\u03b1-to-\\u03b2 cell transdifferentiation, reduced visceral fat, improved glucose tolerance, and enlarged testes with delayed age-related regression [#10, #15, #14]. Beyond ligand sequestration, FSTL3 has an intranuclear role enhancing AF10 oligomerization and AF10-mediated transcription [#12], and in cancer it acts through activin-independent routes\\u2014stabilizing c-Myc to promote immune evasion [#17], binding transferrin receptor TfR1 to activate AKT/mTOR and drive vasculogenic mimicry [#20], and modulating the SLC25A10/succinate/DLAT axis to govern cuproptosis susceptibility [#21].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of FSTL3 from a leukemia-associated chromosomal translocation established it as a novel secreted member of the follistatin family, framing later questions about its ligand-binding function.\",\n      \"evidence\": \"cDNA cloning and molecular characterization of a t(11;19) translocation in B-cell CLL\",\n      \"pmids\": [\"9671416\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No ligand or binding partner identified at cloning stage\", \"Functional role of the translocation unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating that FSTL3 binds activin and is itself induced by TGF-\\u03b2/activin via direct Smad3/4 promoter binding defined it as a transcriptionally regulated activin antagonist within a feedback loop.\",\n      \"evidence\": \"Immunoprecipitation/Far-Western binding assays, promoter reporter with deletion/point mutagenesis, dominant-negative Smad, and EMSA\",\n      \"pmids\": [\"11274757\", \"11451569\", \"11571638\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative ligand selectivity across activin isoforms not yet resolved\", \"Structural basis of antagonism unknown\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showing FSTL3 blocks activin-induced gene transcription and growth inhibition while being activin-inducible closed the negative feedback loop functionally.\",\n      \"evidence\": \"Transcriptional reporter and HepG2 growth-inhibition assays with phospho-Smad2 readout\",\n      \"pmids\": [\"11948405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of feedback not yet tested\", \"Ligand specificity beyond activin A not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Quantifying differential binding and neutralization of activin A versus activin B established FSTL3 as a ligand-selective antagonist rather than a pan-activin sink.\",\n      \"evidence\": \"Binding assays and 293-cell neutralization reporter assays\",\n      \"pmids\": [\"12697670\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of isoform discrimination not defined\", \"Selectivity against other TGF-\\u03b2 ligands untested here\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Mapping the absence of a heparin-binding sequence and the trade-off between heparin and activin binding explained why FSTL3, unlike follistatin, does not bind cell surfaces, distinguishing their bioavailability.\",\n      \"evidence\": \"Domain-insertion mutagenesis with heparin affinity, cell-surface binding, activin binding, and pituitary FSH bioassay\",\n      \"pmids\": [\"15471966\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological consequence of non-surface localization not directly tested\", \"Whether soluble distribution alters tissue targeting unmeasured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery of direct interactions with fibronectin and ADAM12, with functional effects on hematopoietic adhesion and osteoclast differentiation, extended FSTL3's roles beyond soluble ligand antagonism into matrix and cellular contexts.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP/pulldown, cell adhesion assays, and osteoclast differentiation assays\",\n      \"pmids\": [\"16336961\", \"15574124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanistic link between these interactions and activin biology unclear\", \"Single-lab interactions without reciprocal in vivo validation\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing TNF-\\u03b1 drives FSTL3 transcription via NF-\\u03baB, with TGF-\\u03b2/Smad potentiation, integrated inflammatory signaling into the control of FSTL3 expression.\",\n      \"evidence\": \"Promoter deletion/reporter analysis, phylogenetic footprinting, and NF-\\u03baB binding assays\",\n      \"pmids\": [\"17395406\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological context of TNF-\\u03b1 induction not established\", \"Cross-talk between NF-\\u03baB and Smad inputs in vivo untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Knockout mice and breast cancer knockdown placed FSTL3 antagonism of activin/myostatin causally upstream of beta-cell mass, glucose homeostasis, visceral fat, and tumor proliferation.\",\n      \"evidence\": \"Homozygous FSTL3 knockout metabolic phenotyping and siRNA silencing with activin-receptor rescue in breast cancer cells\",\n      \"pmids\": [\"17229845\", \"17671190\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific contributions not dissected\", \"Distinguishing activin- versus myostatin-driven phenotypes incomplete\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying nuclear FSTL3 interaction with AF10 and enhancement of its transcriptional activity revealed an intranuclear function distinct from secreted ligand antagonism.\",\n      \"evidence\": \"Yeast two-hybrid, Far-Western, co-IP in COS-7, oligomerization, and Gal4 transactivation assays\",\n      \"pmids\": [\"17868029\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of nuclear entry for a secreted protein unexplained\", \"Endogenous chromatin targets of FSTL3/AF10 unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The crystal structure of the FSTL3\\u2013activin A complex defined the molecular mechanism of antagonism\\u2014two FSTL3 molecules encircling the ligand to block all receptor sites\\u2014and the N-terminal domain basis of specificity.\",\n      \"evidence\": \"2.5 \\u00c5 X-ray crystallography with domain-swap binding studies\",\n      \"pmids\": [\"18768470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structures with other ligands (activin B, myostatin) not solved\", \"Conformational dynamics in solution not addressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Lineage tracing showing increased \\u03b1-to-\\u03b2 cell transdifferentiation in knockouts, reproduced by activin treatment, identified a cell-fate mechanism underlying FSTL3's control of beta-cell mass.\",\n      \"evidence\": \"Gluc-Cre/YFP lineage tracing, flow cytometry, and activin treatment of isolated islets\",\n      \"pmids\": [\"26727106\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Human relevance of transdifferentiation not established\", \"Downstream beta-cell maturation program undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Testicular enlargement and delayed aging in knockouts, with elevated AKT/SIRT1 signaling, linked FSTL3 ligand antagonism to AKT pathway cross-talk in reproductive tissue.\",\n      \"evidence\": \"FSTL3 knockout histomorphometry and western blot for AKT/SIRT1\",\n      \"pmids\": [\"23407452\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mechanistic connection between activin release and AKT activation unproven\", \"Single-model finding\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Discovery that FSTL3 stabilizes c-Myc by suppressing its ubiquitination to upregulate PDL1/IDO1, plus a selective neutralizing antibody enhancing islet insulin secretion, revealed activin-independent oncogenic activity and therapeutic targetability.\",\n      \"evidence\": \"Co-IP with domain mapping, ubiquitination assays, FSTL3-knockout immunocompetent tumor models, and FP-101 neutralizing antibody islet assays\",\n      \"pmids\": [\"38302412\", \"33539535\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How secreted FSTL3 accesses cytoplasmic/nuclear c-Myc unresolved\", \"Antibody efficacy in vivo for diabetes not yet established\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Mapping KDM1B-driven H3K9me2 loss at the FSTL3 promoter under prenatal dexamethasone defined an epigenetic route to FSTL3 upregulation that impairs blood-testis barrier function via reduced TGF-\\u03b2 signaling.\",\n      \"evidence\": \"ChIP for H3K9me2, dexamethasone treatment of Sertoli cells, and in vivo rat model\",\n      \"pmids\": [\"38472317\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generalizability beyond dexamethasone exposure unknown\", \"Human translation untested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Multiple cancer studies established new activin-independent FSTL3 axes\\u2014TfR1/AKT/mTOR-driven vasculogenic mimicry, SLC25A10/succinate/DLAT-controlled cuproptosis, and ZNF454-repressed HIF-1\\u03b1 glycolysis\\u2014broadening its role in tumor metabolism and metastasis.\",\n      \"evidence\": \"Co-IP/binding assays, scRNA-seq, CRISPR screens, metabolomics/succinylation assays, ChIP/luciferase, and in vivo metastasis/xenograft models with antibody neutralization\",\n      \"pmids\": [\"41053124\", \"41996175\", \"41522747\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these axes operate through the same secreted FSTL3 pool is unclear\", \"Interplay between activin-dependent and activin-independent functions undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a secreted activin antagonist accesses intracellular and nuclear targets (c-Myc, AF10) and whether its diverse cancer-associated metabolic and signaling functions share a unifying mechanism.\",\n      \"evidence\": null,\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No mechanism for cellular re-entry or nuclear localization of secreted FSTL3\", \"Integration of activin-dependent and activin-independent roles not established\", \"Structural basis of TfR1 and c-Myc binding undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 4, 11, 13]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [13, 6]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 2, 6]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 11, 3]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [10, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [17, 20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"INHBA\", \"FN1\", \"ADAM12\", \"AF10\", \"MYC\", \"TFRC\", \"SLC25A10\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}